![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Bohm, U Schmidt, P Gierschik, RH Schwinger, S Bohm and E Erdmann
Klinik III fur Innere Medizin, Universitat zu Koln, Germany.
Halothane has been reported to sensitize the myocardium towards the effects of exogenous catecholamines in patients and laboratory animals. This study was aimed at investigating the catecholamine-sensitizing effects of halothane as well as the underlying subcellular mechanisms in human myocardium. Halothane augmented the positive inotropic effect of isoprenaline but not of Ca2+. The increase of the effect of isoprenaline by halothane was more pronounced in failing myocardium, with increased Gi, than in nonfailing donor hearts. Halothane (1%) increased basal as well as isoprenaline-, NaF-, cholera toxin-, and guanylylimidodiphosphate [Gpp(NH)p]-stimulated adenylate cyclase in human myocardial membranes (p < 0.05). Treatment of membranes with pertussis toxin increased adenylate cyclase by 40% and abolished the effect of halothane. Halothane had no effect on forskolin-stimulated adenylate cyclase. The same results, i.e., a pertussis toxin-sensitive increase of adenylate cyclase stimulation by halothane, were obtained in S49 cyc-, wild-type, or recombinant Gs alpha-reconstituted cyc- cell membranes. Carbachol-stimulated guanosine-5'-O-(3- [35S]thio)triphosphate binding was not influenced by halothane, but halothane attenuated the inhibition of adenylate cyclase by Gpp(NH)p in S49 cyc- cells. These data show that halothane stimulates adenylate cyclase and sensitizes adenylate cyclase after stimulation by beta- adrenoceptor agonists and guanine nucleotides due to an impairment of Gi alpha function. This mechanism may play a role in the halothane sensitization of myocardial adenylate cyclase towards catecholamines.
This article has been cited by other articles:
|
|
 |
|
  S. Milovic, B. Steinecker-Frohnwieser, W. Schreibmayer, and L. G. Weigl The Sensitivity of G Protein-activated K+ Channels toward Halothane Is Essentially Determined by the C Terminus J. Biol. Chem., August 13, 2004; 279(33): 34240 - 34249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Rebecchi and S. N. Pentyala Anaesthetic actions on other targets:protein kinase C and guanine nucleotide-binding proteins Br. J. Anaesth., July 1, 2002; 89(1): 62 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Weigl and W. Schreibmayer G Protein-Gated Inwardly Rectifying Potassium Channels Are Targets for Volatile Anesthetics Mol. Pharmacol., August 1, 2001; 60(2): 282 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bohm, S. Ettelbruck, M. Flesch, W. H van Gilst, A. Knorr, C. Maack, Y. M Pinto, M. Paul, A. C.H Teisman, and O. Zolk {beta}-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy Cardiovasc Res, October 1, 1998; 40(1): 146 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sitzler, O. Zolk, U. Laufs, M. Paul, and M. Bohm Vascular ß-Adrenergic Receptor Adenylyl Cyclase System From Renin-Transgenic Hypertensive Rats Hypertension, May 1, 1998; 31(5): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bohm, O. Zolk, M. Flesch, F. Schiffer, P. Schnabel, J.-P. Stasch, and A. Knorr Effects of Angiotensin II Type 1 Receptor Blockade and Angiotensin-Converting Enzyme Inhibition on Cardiac ß-Adrenergic Signal Transduction Hypertension, March 1, 1998; 31(3): 747 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bohm, M. Castellano, E. Agabiti-Rosei, M. Flesch, M. Paul, and E. Erdmann Dose-Dependent Dissociation of ACE-Inhibitor Effects on Blood Pressure, Cardiac Hypertrophy, and ß-Adrenergic Signal Transduction Circulation, November 15, 1995; 92(10): 3006 - 3013. [Abstract] [Full Text]
|
|
|
|
|
|
M. Bohm, C. Grabel, A. Knorr, and E. Erdmann Treatment in Hypertensive Cardiac Hypertrophy, I : Neuropeptide Y and ß-Adrenoceptors Hypertension, May 1, 1995; 25(5): 954 - 961. [Abstract] [Full Text]
|
|
|
|
|
|
M. Bohm, C. Grabel, M. Flesch, A. Knorr, and E. Erdmann Treatment in Hypertensive Cardiac Hypertrophy, II : Postreceptor Events Hypertension, May 1, 1995; 25(5): 962 - 970. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
